A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Grants and Contracts Details

StatusActive
Effective start/end date9/2/225/25/23

Funding

  • Vertex Pharmaceuticals Inc: $2.00